Identifying Characteristics of Bone Marrow Failure Syndromes
NCT00315419 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450
Last updated 2010-04-21
Summary
Bone marrow failure syndromes (BMFS) are rare disorders characterized by dysfunctional hematopoietic stem cells, which give rise to all red and white blood cells. The deficiency of blood cells, or cytopenia, caused by this malfunction leads to an assortment of diseases and disorders, all of which are characterized as BMFS. Because these diseases are rare, conducting research on them is difficult, and standards of treatment for most BMFS have yet to be developed. This study will collect clinical and laboratory data from people with BMFS to identify the characteristics and biological markers associated with these diseases over time. This information will assist doctors and researchers to develop better therapies and diagnostic tests that will help improve the management of BMFS and cytopenias.
Conditions
- Bone Marrow Failure Syndromes
- Anemia, Aplastic
- Myelodysplastic Syndromes
- Hemoglobinuria, Paroxysmal
- Red-Cell Aplasia, Pure
- Purpura, Thrombocytopenic
- Leukemia, Lymphocytic
Sponsors & Collaborators
-
Rare Diseases Clinical Research Network
collaborator NETWORK -
Office of Rare Diseases (ORD)
lead NIH
Principal Investigators
-
Jaroslaw P. Maciejewski, MD, PhD · The Cleveland Clinic
Eligibility
- Min Age
- 11 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-04-30
- Primary Completion
- 2009-07-31
- Completion
- 2009-07-31
Countries
- United States
Study Locations
More Related Trials
-
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia
NCT00005891 ·Status: COMPLETED ·Phase: NA
-
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
NCT05350748 ·Status: RECRUITING
-
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia
NCT00005892 ·Status: COMPLETED ·Phase: NA
-
Sickle Cell Disease Conditioning for Bone Marrow Transplant
NCT00968162 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
NCT00005893 ·Status: COMPLETED ·Phase: NA
-
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
NCT01203722 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
NCT01962415 ·Status: RECRUITING ·Phase: PHASE2
-
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
NCT00005852 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
NCT06517641 ·Status: RECRUITING ·Phase: PHASE2
-
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
NCT02828592 ·Status: RECRUITING ·Phase: PHASE2
-
Non-Myeloablative Conditioning and Bone Marrow Transplantation
NCT01850108 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia
NCT00005898 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow
NCT02757885 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
NCT00255684 ·Status: TERMINATED ·Phase: NA
-
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
NCT01049854 ·Status: COMPLETED ·Phase: PHASE2
-
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT03579875 ·Status: RECRUITING ·Phase: PHASE2
-
Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders
NCT00489281 ·Status: TERMINATED ·Phase: PHASE2
-
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
NCT00253552 ·Status: TERMINATED ·Phase: NA
-
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
NCT00258427 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers
NCT00899795 ·Status: COMPLETED
-
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
NCT00008307 ·Status: UNKNOWN ·Phase: PHASE2
-
Unrelated And Partially Matched Related Donor PSCT w/ T Cell Receptor (TCR) αβ Depletion for Patients With BMF
NCT03047746 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Human Placental-Derived Stem Cell Transplantation
NCT01586455 ·Status: COMPLETED ·Phase: PHASE1
-
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
NCT02171104 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
NCT00202917 ·Status: COMPLETED ·Phase: PHASE1/PHASE2